Clinical and immunohistochemical assessment of the effect of cyclosporin in keratinocytes and dermal dendrocytes in psoriasis

Journal of Cutaneous Pathology

Volumn 34, Issue 1, 2007, Pages 15-21

  Lago, Eduardo ^a,c   Carneiro, Sueli ^a,b   Cuzzi, Tullia ^a   Magalhães, Geraldo ^a   Cássia, Flavia ^a   Pessanha, Fátima ^a   Ramos E Silva, Marcia ^a  

^a FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^b STATE UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^c NONE   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

BLOOD CLOTTING FACTOR 8A; CREATININE; CYCLOSPORIN; CYTOKERATIN 10; CYTOKERATIN 14; CYTOKERATIN 16; URIC ACID;

ADULT; AGED; ARTICLE; BIOPSY; CELL DIFFERENTIATION; CELL PROLIFERATION; CLINICAL ARTICLE; CREATININE BLOOD LEVEL; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOHISTOCHEMISTRY; KERATINOCYTE; MALE; PROTEIN EXPRESSION; PSORIASIS; URIC ACID BLOOD LEVEL;

ADULT; AGED; CELL DIFFERENTIATION; CELL PROLIFERATION; CYCLOSPORINE; DENDRITIC CELLS; DERMIS; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOSUPPRESSIVE AGENTS; KERATIN-10; KERATIN-14; KERATIN-16; KERATINOCYTES; MALE; MIDDLE AGED; PSORIASIS; SEVERITY OF ILLNESS INDEX; TREATMENT OUTCOME;

EID: 33846078445     PISSN: 03036987     EISSN: 16000560     Source Type: Journal    
DOI: 10.1111/j.1600-0560.2006.00571.x     Document Type: Article

References (34)

1. Farber EM, Nall ML. The natural history of psoriais in 5,600 patients. Dermatologica 1974; 148: 1.
2. Farber EM, Bright RD, Nall ML. Psoriasis a questionnaire survey of 2,144 patients. Arch Dermatol 1968; 98: 248.
3. Christophers E. Psoriasis-epidemiology and clinical spectrum. Clin Exp Dermatol 2001; 26: 314.
4. Grossman RM, Chevret S, Abi-Rached J, Blanchet F, Dubertret L. Long-term of cyclosporine in the treatment of psoriasis. Arch Dermatol 1996; 132: 623.
5. Borel JF, Feurer C, Gubler HU, Stahelin H. Biological effects of cyclosporin A: a new antilymphocytic agent. Agents Actions 1976; 6: 468.
6. Mueller W, Herrmann B. Cyclosporine A for psoriasis. N Engl J Med 1979; 301: 555.
7. Moll R, Franke WW, Schiller DL, Geiger B, Krepler R. The catalog of human cytokeratins: patterns of expression in normal epithelia, tumors and cultured cells. Cell 1982; 31: 11.
8. Eckert RL, Crish JF, Robinson NA. The epidermal keratinocyte as a model for the study of gene regulation and cell differentiation. Physiol Rev 1997; 77: 397.
9. Cribier B, Grosshans E. Les cytokératines dans la peau et les muqueusesmalpighiennes. Ann Dermatol Venereol 1993; 120: 327.
10. Nelson WG, Sun TT. The 50- and 58 kdalton keratin classes as molecular markers for stratified aquamous epithelia: cell culture studies. J Cell Biol 1983; 97: 244.
11. Purkis PE, Steel JB, Mackenzie IC, et al. Antibody markers of basal cells in complex epithelia. J Cell Sci 1990; 97: 39.
12. Ivanyi D, Ansink A, Groeneveld E, et al. New monoclonal antibodies recognizing epidermal differentiation-associated keratins in formalin-fixed, paraffin-embedded tissue. Keratin 10 expression in carcinoma of the vulva. J Pathol 1989; 159: 7.
13. Headington JT. The dermal dendrocyte. Adv Dermatol 1986; 1: 159.
14. Cerio R, Griffiths CE, Cooper KD, Nickoloff BJ, Headington JT. Characterization of factor XIIIa positive dermal dendritic cells in normal and inflamed skin. Br J Dermatol 1989; 121: 421.
15. Braverman IM. The dermal microvascular unit: relationship to immunological processes and dermal dendrocytes. In Nickoloff BJ, ed. Dermal immune system. Boca Raton: CRC Press, 1993; 91.
16. Sueki H, Telegan B, Murphy GF. Computer-assisted three-dimensional reconstruction of human dermal dendrocytes. J Invest Dermatol 1995; 105: 704.
17. Kirby B, Richards HL, Woo P, et al. Physical and psychologic measures are necessary to assess overall psoriasis severity. J Am Acad Dermatol 2001; 45: 72.
18. Cooper KD, Baadsgaard O, Ellis CN, Duell E, Voorhees JJ. Mechanisms of cyclosporine A inhibition of antigen-presenting activity in uninvolved and lesional psoriatic epidermis. J Invest Dermatol 1990; 94: 649.
19. Cooper KD, Voorhees JJ, Fisher GJ, et al. Effects of cyclosporine on immunologic mechanisms in psoriasis. J Am Acad Dermatol 1990; 23: 1318.
20. Ho VC, Griffiths CE, Berth-Jones J, et al. Intermittent short courses of cyclosporine microemulsion for the long-term management of psoriasis: a 2-year cohort study. J Am Acad Dermatol 2001; 44: 643.
21. Shupack J, Abel E, Bauer E, et al. Cyclosporine as maintenance therapy in patients with severe psoriasis. J Am Acad Dermatol 1997; 36: 423.
22. Kelly GE, Sheil AG, Wass J, Zbroja RA. Effects of ultraviolet radiation and immunosuppresive therapy on mouse epidermal cell kinetics. Br J Dermatol 1986; 114: 197.
23. Krueger JG. The immunologic basis for the treatment of psoriasis with new biologic agents. J Am Acad Dermatol 2002; 46: 1.
24. Barrandon Y, Green H. Cell migration is essential for sustained growth of keratinocytes colonies: the roles of transforming growth factor-alpha and epidermal growth factor. Cell 1987; 50: 1131.
25. Saunders NA, Jetten AM. Control of growth regulatory and differentiation-specific genes in human epidermal keratinocytes by interferon gamma. Antagonism by retinoic acid and transforming growth factor beta 1. J Biol Chem 1994; 269: 2016.
26. Leigh IM, Navsaria H, Purkis PE, et al. Keratins (K16 e K17) as markers of keratinocyte hyperproliferation in psoriasis in vivo and in vitro. Br J Dermatol 1995; 133: 501.
27. Cerio R, Spaull J, Jones EW. Histiocytoma cutis: a tumor of dermal dendrocytes (dermal dendrocytoma). Br J Dermatol 1989; 120: 197.
28. Morganroth GS, Chan LS, Weinstein GD, Voorhees JJ, Cooper KD. Proliferating cells in psoriatic dermis are comprised primarily of T cells, endothelial cells, and factor XIIIa+ perivascular dendritic cells. J Invest Dermatol 1991; 96: 333.
29. Deguchi M, Aiba S, Ohtani H, et al. Comparison of the distribution and numbers of antigen-presenting cells among T-lymphocyte-mediated dermatoses: CD1a+, factor XIIIa+, and CD68+ cells in eczematous dermatitis, psoriasis, lichen planus and graft-versus-host disease. Arch Dermatol Res 2002; 284: 297.
30. Nickoloff BJ, Karabin GD, Barker JN, et al. Cellular location of interleukin-8 and its inducer, tumor necrosis factor-alpha in psoriais. Am J Pathol 1991; 138: 129.
31. Tse Y, Cooper KD. Cutaneous dermal Ia+ cells are capable of initiating delayed type hypersensitivity response. J Invest Dermatol 1990; 94: 267.
32. Finzi AF, Mozzanica N, Cattaneo A, Chiappino G, Pigatto PD. Effectiveness of cyclosporine treatment in severe psoriasis: a clinical and immunologic study. J Am Acad Dermatol 1989; 21: 91.
33. Yamauchi PS, Rizk D, Kormeili T, Patnaik R, Lowe NJ. Current systemic therapies for psoriasis: where are we now? J Am Acad Dermatol 2003; 49: S66.
34. Baker BS, Griffiths CE, Lambert S, et al. The effects of cyclosporin A on T lymphocyte and dendritic cell sub-populations in psoriasis. Br J Dermatol 1987; 116: 503.